- Home
- ANIX vs GNLX Comparison
ANIX vs GNLX Comparison
Compare ANIX & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANIX
- GNLX
- Stock Information
- Founded
- ANIX 1982
- GNLX 2001
- Country
- ANIX United States
- GNLX United States
- Employees
- ANIX N/A
- GNLX N/A
- Industry
- ANIX Biotechnology: Pharmaceutical Preparations
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- ANIX Health Care
- GNLX Health Care
- Exchange
- ANIX Nasdaq
- GNLX Nasdaq
- Market Cap
- ANIX 108.9M
- GNLX 110.9M
- IPO Year
- ANIX 1987
- GNLX 2023
- Fundamental
- Price
- ANIX $3.23
- GNLX $3.09
- Analyst Decision
- ANIX Strong Buy
- GNLX Strong Buy
- Analyst Count
- ANIX 3
- GNLX 4
- Target Price
- ANIX $9.00
- GNLX $17.75
- AVG Volume (30 Days)
- ANIX 242.7K
- GNLX 137.5K
- Earning Date
- ANIX 05-28-2025
- GNLX 08-13-2025
- Dividend Yield
- ANIX N/A
- GNLX N/A
- EPS Growth
- ANIX N/A
- GNLX N/A
- EPS
- ANIX N/A
- GNLX N/A
- Revenue
- ANIX N/A
- GNLX N/A
- Revenue This Year
- ANIX N/A
- GNLX N/A
- Revenue Next Year
- ANIX N/A
- GNLX N/A
- P/E Ratio
- ANIX N/A
- GNLX N/A
- Revenue Growth
- ANIX N/A
- GNLX N/A
- 52 Week Low
- ANIX $2.07
- GNLX $1.60
- 52 Week High
- ANIX $4.20
- GNLX $5.89
- Technical
- Relative Strength Index (RSI)
- ANIX 51.86
- GNLX 56.10
- Support Level
- ANIX $3.18
- GNLX $2.75
- Resistance Level
- ANIX $3.33
- GNLX $3.17
- Average True Range (ATR)
- ANIX 0.22
- GNLX 0.23
- MACD
- ANIX -0.05
- GNLX -0.00
- Stochastic Oscillator
- ANIX 13.94
- GNLX 56.94
About ANIX Anixa Biosciences Inc.
Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.